Fichero a descargar de la publicación mostrada - Sociedad ...

Octubre 2011 INFECCIONES RELACIONADAS CON CATÉTERES VASCULARES Pág. 49______________________________________________________________________________130. Sandoe JA, Witherden IR, Au-Yeung HK, Kite P, Kerr KG, Wilcox MH. Enterococcal intravascular catheterrelatedbloodstream infection: management and outcome of 61 consecutive cases. J Antimicrob Chemother2002; 50:577-82.131. Mainardi JL, Gutmann L, Acar JF, Goldstein FW. Synergistic effect of amoxicillin and cefotaxime againstEnterococcus faecalis. Antimicrob Agents Chemother 1995; 39:1984-7.132. Gavalda J, Torres C, Tenorio C, et al. Efficacy of ampicillin plus ceftriaxone in treatment of experimentalendocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob AgentsChemother 1999; 43:639-46.133. Cannon JP, Pachucki CT, Aneziokoro CO, Lentino JR. The Effectiveness and safety of oral linezolid asprimary or secondary treatment of bloodstream infections. Infectious Diseases in Clinical Practice 2006; 14:221-6.134. Cha R, Rybak MJ. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in anin vitro pharmacodynamic model with simulated endocardial vegetations. Diagn Microbiol Infect Dis 2003;47:539-46.135. Pankey G, Ashcraft D, Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faeciumresistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005; 49:5166-8.136. Snydman DR, McDermott LA, Jacobus NV. Evaluation of in vitro interaction of daptomycin with gentamicinor beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves. JChemother 2005; 17:614-21.137. Warren RE. Daptomycin in endocarditis and bacteraemia: a British perspective. J Antimicrob Chemother2008; 62 Suppl 3:iii25-iii33.138. Arias CA, Torres HA, Singh KV, et al. Failure of daptomycin monotherapy for endocarditis caused by anEnterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations andevidence of in vivo loss of the vanA gene cluster. Clin Infect Dis 2007; 45:1343-6.139. Linden PK, Moellering RC Jr., Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faeciuminfections with quinupristin/dalfopristin. Clin Infect Dis 2001; 33:1816-23.140. Weinstein RA, Fridkin SK. The changing face of fungal infections in health care dettings. Clin Infect Dis2005; 41:1455-60.141. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidaemia in Europe: results of 28-monthEuropean Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin MicrobiolInfect Dis 2004; 23:317-22.142. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplantrecipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181:309-16.143. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicentersurveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research andTreatment of Cancer (EORTC). Clin Infect Dis 1999; 28:1071-9.144. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dosefluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequencesin nonneutropenic subjects. Clin Infect Dis 2003; 36:1221-8.145. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl JMed 2007; 356:2472-82.146. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis:2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-35.